

January 3, 2017

Initiation

Navin Fluorine International Ltd

Fluorinating the way ahead

Outperformer

Navin Fluorine International Ltd (NFIL) a pioneer in Fluorochemical industry has over 45 years of experience in fluorine chemistry and refrigerant science space. Leveraging on its dominance in the sector NFIL diversified into specialty chemicals segment in the year 2000 and used windfall from carbon credits to venture into Custom Research and Manufacturing Services (CRAMS) in 2010. Both these segments are high value businesses with significant entry barriers. NFIL has also entered into Joint Venture (JV) with Piramal Enterprises Ltd (PEL) and partnership with Honeywell (US), these ventures will enhance future growth. Going ahead, we expect revenue and PAT CAGR of 15% and 27% respectively over FY16-19E and EBITDA margins of ~22% in FY19E. Given its dominance in fluorination business and favourable growth outlook, we initiate coverage with target price of ₹2,900, valuing the stock at 18x its 12M Sep'18E PE.

Reshaped business model through systematic capital allocation: NFIL generated windfall income of around ₹400 crore over FY11-13, which it used to enter into the CRAMS segment. It also fully acquired Manchester Organics Ltd (UK) for ₹93 crore in FY16 to further strengthen its CRAMS business. Further, to secure future source of key raw material (Fluorspar) NFIL entered into a JV with Gujarat Mineral Development Corporation (GMDC).

Surge in share of key segments to drive growth: Scaling up the value chain NFIL entered into specialty chemical and CRAMS segments. These segments have relatively higher margins and mainly cater to the pharmaceutical, agro chemical, crop protection and specialty chemical sectors. In the CRAMS segment, the company commenced operation at the new Dewas facility in FY16 and at its peak can generate revenue of around ₹180 crore.

Investment in new avenues to further boost growth: NFIL entered into a JV with PEL (holds 51% stake) in 2014 to manufacture fluorinated intermediate exclusively for PEL. The products are in validation stage and will soon start commence large scale production. In Mar'16, NFIL entered into a partnership with Honeywell (US) to manufacture 'HFO 1234 yf' gas which is a near replacement for R-134a (used in vehicle air conditioning systems).

Strong balance sheet and healthy return ratios: NFIL's revenue and PAT has increased from FY13-16 at a CAGR of 7% and 24%, respectively. EBITDA margin has expanded by 230 bps to 17% in FY16. Going ahead, we expect revenue and PAT CAGR of 15% and 27% respectively over FY16-19E and EBITDA margins of ~22% in FY19E. The company has minimum debt on balance sheet and RoIC and RoE's are expected to increase further from 19% and 14% respectively in FY16 to 31% and 20% in FY19E.

Risk factors: 1) Lower utilization of new CRAMS facility; 2) Change in phase out plan of R-22 gas; 3) Stiff competition from Chinese players.

Valuation: We believe traction from CRAMS and specialty chemical segment along with commercialization of Piramal JV and Honeywell partnership will be the future growth drivers. Given NFIL's dominance in the fluorination space and favourable growth outlook, we initiate coverage with a target price of ₹2,900, valuing the stock at 18x its 12M Sep'18E PE.

Financial Summary (Consolidated)

Y/E Mar (₹ Cr.)	Revenue	YoY (%)	EBITDA	EBITDA (%)	Adj. PAT	YoY (%)	Adj. EPS (₹)	P/E (x)	EV/EBITDA(x)	RoE (%)
FY15A	592	21.7	72	12.2	58	6.5	59.53	42.7	34.1	10.2
FY16A	680	14.9	117	17.3	84	43.4	85.34	29.8	21.2	13.5
FY17E	767	12.8	157	20.4	115	37.9	117.73	21.6	15.5	16.9
FY18E	889	16.0	194	21.8	144	24.7	146.77	17.3	12.3	18.8
FY19E	1,046	17.6	228	21.8	172	19.6	175.49	14.5	10.2	19.8

Source: Company, Centrum Wealth Research

Recommendation

Current Market Price (₹)	2,541
Target Price (₹)	2,900
Potential upside	14.1%
Sector Relative to Market	Outperform
Stock Relative to Sector	In-line


Stock Information

BSE Code	532504
NSE Code	NAVINFUOR
Face value (₹/share)	10.0
No. of shares (Cr.)	1.0
Market Cap (₹ Cr.)	2,446
Free float (₹ Cr.)	1,500
52 Week H / L (₹)	2,875/1,262
Avg. Daily turnover (12M, ₹ Cr.)	4.4

Shareholding Pattern (%)

	Sep-16	Sep-15
Promoter	38.7	38.8
Mutual Funds	17.6	16.9
FII/FPI	10.7	7.6
Others including Public	33.0	36.7

Price Performance (%)



Source: Bloomberg, Centrum Wealth Research

Price Performance (%)

	1M	3M	6M	12M
Navin Fluorine Intl.	10.2	11.1	23.6	30.3
S&P BSE Midcap	(0.1)	(9.6)	2.7	8.3

Source: Bloomberg, Centrum Wealth Research


Abdulkader Puranwala, Research Analyst
Siddhartha Khemka, Sr. VP Research

About the company

Navin Fluorine International Ltd (NFIL) established in 1967 is a part of the Arvind Mafatlal Group. It is one of the oldest refrigerant gas players in Asia. NFIL's Mafron brand is a generic name for refrigerant gases in India and a preferred choice for original equipment manufacturers (OEM), service technicians and equipment owners. The company operates one of the largest integrated fluorochemicals complexes in India with two manufacturing facilities located in Gujarat (Surat and Dahej) and one in Madhya Pradesh (Dewas).

NFIL initially used to manufacture refrigerant gases which are used as cooling agent in air conditioners, refrigerators and commercial establishments and inorganic fluorides used as raw materials in the metal and glass industry. In the year 2000, NFIL decided to move up the value chain and ventured into the speciality chemicals segment and further scaled up operations by entering into the CRAMS segment in 2011.

Exhibit 1: Key milestones of the company



Source: Company, Centrum Wealth Research

NFIL operates in 4 lines of businesses, the base business of Refrigerants, Specialty chemicals, Inorganic fluoride and CRAMS. The products offered through these segments cater to different industries including air conditioning (OEM), Fluoropolymer, Pharmaceuticals, Agrochemicals & Crop protection, Fragrance, Oil & Gas, Stainless Steel among others. NFIL's rich clientele includes global players like Syngenta, BASF, Whirlpool, LG, Samsung, Carrier, Blue Star, Bayer, Clariant, Lupin and Sun Pharma.

Exhibit 2: Business Segments

	Refrigerants	Inorganic Fluoride	Speciality chemical	CRAMS
Revenue contribution (FY16)	34%	15%	38%	14%
Geographic distribution (Revenue FY16)	Domestic 62%, Exports 38%	Domestic 89%, Exports 11%	Domestic 54%, Exports 46%	Exports 100%
Key export market	Europe, Middle East, South-East Asia and South Africa	US, Europe, Middle East and South Korea	Asia	US and Europe
Products	HCFC 22, HCFC 22 PTFE Grade, HFC 134a, HFC 404a, HFC 410a	Aluminium Fluoride, Ammonium Bifluoride, Anhydrous Hydrofluoric	Over 48 Fluorine based products	Custom chemical syntheses of fluorinated compounds
Industry	Air-conditioning, Pharmaceuticals and Fluoropolymer	Oil & Gas, Stainless Steel, Electronics and Pharmaceuticals	Pharmaceuticals, Crop protection and Fragrances	Pharmaceuticals, Agro chemical and Specialty chemicals
Revenue contribution (FY19E)	25%	14%	30%	30%


Source: Company, Centrum Wealth Research

Reshaped business model through systematic capital allocation

The refrigerant business of NFIL mainly consists of R-22 gas which is used in air-conditioners and as a feedstock in pharmaceuticals and specialty chemicals industry. An international carbon credit system was approved in conjunction with the Kyoto Protocol in 1997 to reduce greenhouse gases and provide incentives to users to bring down carbon emission below their quota. As per the system, carbon credits could be earned if a company pollutes less than its quota and in turn could trade these credits in the international market to companies that pollute more.

NFIL generated income of around ₹400 crore over FY11-13 from trading in these carbon credits, post which in FY14 the EU levied a ban on trading of carbon credit. NFIL utilized this windfall income to diversify its presence in higher margin CRAMS business by investing ₹60 crore for setting up a multi-product plant in Dewas. To further strengthen its CRAMS business, NFIL invested around ₹93 crore (₹33 crore in FY12 for 51% stake and ₹60 crore in FY16 for the balance) to acquire 100% stake in Manchester Organics Ltd (MOL).

Exhibit 3: Scaling up the value chain




Source: Company, Centrum Wealth Research

The refrigerant business in the near term is unlikely to be affected due to the mandatory phase out of R-22 gas as the government has banned import of pre-filled R-22 gas cylinders. It is expected to be steady cash generator for NFIL as even though the segment may not see any volume growth, realization from the segment are expected to increase as demand for R-22 gas will outpace supply due to the imposition of production cuts.

In order to secure its raw material source and reduce price volatility, NFIL (holds 25%) and Gujarat Fluorochemicals Ltd (GFL) entered into a joint venture (JV) - Swarnim Gujarat Fluorspar Pvt Ltd with Gujarat Mineral Development Corporation Ltd (GMDC) pursuant to which entire quantity of acid grade fluorspar produced by GMDC will be bought equally by NFIL and GFL. The JV is yet to commence operations.

Further NFIL has incorporated a trading outfit in China – Navin Fluorine (Shanghai) Co. Ltd to ensure smooth supply of other key raw materials. The company plans to invest ₹13 crore over the next 20 years in this venture.

Exhibit 4: Key raw material cost trend continues to be downward



Source: Company, Centrum Wealth Research

Surge in share of key segments to drive growth


To capitalize on its expertise in the Fluorochemical industry, NFIL diversified its revenue base by entering the speciality chemical segment in 2000 and CRAMS in 2011.

In the speciality chemicals segment, The company is regularly enhancing its product portfolio and is now offering 48 products including key products like Borontrifluoride, fluorobenzene and benzotrifluoride mainly catering to the pharmaceutical, agrochemical and petrochemicals industries.


Due to the overall slowdown in the global agrochemical industry NFIL is currently facing headwinds in this business. However, the management is confident that growth in this segment would bounce back in the near term because of introduction of new products and addition of new clients. We expect growth in the segment to bounce back in FY18 and expect it to increase at a CAGR of 10% over FY17-19E.

Exhibit 5: Geographical revenue distribution of key businesses (FY16)

Specialty Chemicals



CRAMS



Source: Company, Centrum Wealth Research


In the CRAMS space, the company is currently working on around 40 molecules to be delivered to more than 20 global pharmaceutical majors. NFIL continues to strengthen its foothold across American, European and Asia Pacific regions with stronger marketing teams across USA, Western Europe and Japan.

NFIL has invested around ₹60 crore to augment its pilot plant facility at Dewas with cGMP compliant contract manufacturing facility to deliver ton level quantities. The new facility has undergone successful customer audits by global pharmaceutical companies and had commenced commercial production at the end of FY16.

The new facility will act as a centre for Innovation which will continue to drive growth. NFIL further plans to continue its investment in research and development of new molecules, new applications and more efficient processing techniques.

The acquisition of Manchester Organics Ltd UK (MOL) will help NFIL gain a higher share in the CRAMS universe of fluorinated molecules. MOL has not only given NFIL access to global innovative pharmaceutical companies but also provided an edge in fluorination chemistries; this has enhanced the company’s overall production capabilities of value added product portfolio in the CRAMS and specialty chemicals segment. We expect robust growth in the CRAMS segment, increasing at a CAGR of 54% to ₹320 crore over FY16-19E.

Exhibit 6: Higher contribution from key segments to drive growth and EBITDA margins




Source: Company, Centrum Wealth Research

Growth in Inorganic Fluorides to bounce back

The inorganic fluoride segment mainly caters to industries like stainless steel, glass, oil & gas, abrasives, electronic industries, pharmaceutical, agrochemicals etc. The volume of products in this segment is high with applications in standard processes.

Over the last couple of year, revenue from this segment had declined due to slowdown in domestic demand and pricing pressure on account of cheaper imports. However, the company's continued focus on strengthening its product portfolio by introducing new products for new applications in industries like electronics and geographical diversification has resulted in a turnaround in business. In H1FY17 revenue from this segment has grown at 20.5% to ₹55 crore and going ahead we expect revenue from this segment to witness a CAGR of 17% to ₹152 crore over FY16-19E.

Exhibit 7: Pick up in Inorganic Fluorides on card



Source: Company, Centrum Wealth Research

JV with Piramal & Honeywell to cater long term benefits

NFIL and Piramal Enterprises Ltd (PEL) in 2014 entered into a JV, Convergence Chemicals Pvt Ltd (CCPL) manufacture fluorinated intermediate used in pharmaceutical industry. As per the agreement NFIL will hold 49% and PEL will have 51% stake in CCPL.

NFIL has set up a dedicated facility for this JV in Dahej for an initial investment of ₹140 crore, which will be equally contributed by NFIL and PEL (equity contribution by NFIL is expected to be around ₹35 crore and balance by debt). Raw materials for this facility will be supplied from NFIL's fluorination plant and the final product will cater to PEL's fast growing 'critical care' segment.

The company is currently conducting trial run of the product from the plant and the final product is under approval with the customer. Post receipt of the approval, full scale commercial production and sale is expected to commence during FY17.

In Mar'16, NFIL entered into a partnership with Honeywell to manufacture Solstice yf (HFO 1234 yf) in India. As per the terms of the agreement, Honeywell will license its proprietary process technologies to produce the refrigerant to NFIL and in turn NFIL will set up a facility in Surat to manufacture HFO 1234 yf exclusively for Honeywell.

HFO-1234yf is a next generation hydro fluoro-olefin (HFO) refrigerant with global warming potential (GWP) less than 1 and is a near replacement for R-134a gas, which is used in vehicle air conditioning systems globally. HFO 1234 yf is also being used in a growing number of stationary air conditioning and commercial refrigeration applications. The demand for HFO 1234 yf in mobile air conditioning is increasing rapidly due to increased global environmental regulations and policies aimed at reducing the global warming impacts of hydro fluorocarbons (HFCs). Further, Honeywell and its key suppliers are investing approximately \$300 million to increase global production capacity for HFO 1234 yf. Production from this plant is expected to start in 2017.

Restructuring of shareholding among promoter group of companies

In Aug'16 as a part of a family settlement and succession plan, the companies under the Arvind Mafatlal group entered into an agreement to restructure the promoter shareholding of the 3 listed companies and other group companies. As per the agreement Mr. Vishad Mafatlal and NFIL will sell its stake in Mafatlal Industries Ltd (MIL) and NOCIL Ltd, while Mr. Hrishikesh Mafatlal, MIL and NOCIL will sell their stake in NFIL. Mr. Hrishikesh Mafatlal the then chairman of NFIL stepped down from the position and was replaced by Mr. Vishad Mafatlal, who was earlier the non-executive promoter and director. Sale of shares held by MIL, NOCIL and NFIL in each other will be done through the stock exchange. NFIL is expected to sell part of its holding in MIL and NOCIL and the balance shares are proposed to be reclassified as public shareholding. In Q2FY17, NFIL sold part of its stake in MIL and NOCIL and recorded a profit on sale of investment of ₹27 crore. As on Sep'16, NOCIL and MIL held 4.8% and 1.2% equity stake respectively in NFIL, while NFIL held 2.4% stake in NOCIL and 7.7% in MIL.

Strong balance sheet and healthy return ratios

NFIL's revenue and PAT has increased at CAGR of 7% and 24% respectively, over FY13-16. EBITDA margin during the period has expanded by 230 bps to 17.3% in FY16 largely on account of fall in raw material prices. The company has minimum debt on its balance sheet and RoE's which were in single digit (9%) in FY13, have increased to over 13% in FY16. Going ahead we expect revenue and PAT CAGR of 15% and 27% respectively over FY16-19E. We expect higher revenue contribution from value added products will further enhance margins by 450 bps to ~22% in FY19E. RoE's are expected to improve to 20% in FY19E.

Exhibit 8: Revenue to grow at steady pace




Source: Company, Centrum Wealth Research

Exhibit 9: EBITDA margins driven by segmental mix




Source: Company, Centrum Wealth Research

Exhibit 10: Further expansion of return ratios on cards



Source: Company, Centrum Wealth Research

Exhibit 11: Set to generate healthy free cash flows



Source: Company, Centrum Wealth Research

Key Risks

- **Lower utilization of new CRAMS facility:** CRAMS segment often faces lumpiness in business; inability to get new orders may result in lower utilization of the facility and hamper the growth prospects of the company.
- **Change in phase out plan of R-22 gas:** An early phase out on use of R-22 gas under the Montreal Protocol may hamper prospects of the refrigerant segment.
- **Stiff competition from China:** NFIL competes with companies in China for some of its molecules. Significant depreciation of Chinese Yuan (CNY) as compared to INR, may lead to increased competition for Indian players.

Exhibit 12: Quarterly Results - Standalone

Y/E Mar (₹ Cr.)	Q2FY16	Q3FY16	Q4FY16	Q1FY17	Q2FY17
Revenue	151	145	190	164	183
YoY Growth %	21.7	(0.5)	29.9	9.3	20.8
Cost of Raw Material	63	70	88	65	79
% of Sales	41.8	48.2	46.3	39.6	43.1
Personnel Expenses	15	15	19	18	18
% of Sales	10.2	10.3	10.1	11.2	10.0
Other Expenses	41	37	47	41	45
% of Sales	27.0	25.7	24.7	25.1	24.6
EBIDTA	31.7	23.0	35.9	39.7	40.6
EBIDTA margin %	21.0	15.8	18.9	24.2	22.3
Depreciation	5	6	6	6	6
Interest	1	1	1	0	0
Other Income	9	4	8	6	6
Exceptional Expense	-	-	-	-	(27)
PBT	35	20	37	39	41
Provision for tax	12	6	6	11	13
Effective tax rate %	33.9	31.9	14.8	27.5	31.3
Net Profit (Adjusted)	23	14	32	29	33
YoY Growth %	130.5	(4.3)	89.7	57.7	43.0
PAT margin %	15.4	9.4	16.6	17.4	18.2

Source: Company, Centrum Wealth Research

Valuation

We believe traction from CRAMS and specialty chemical segment along with commercialization of Piramal JV and Honeywell partnership will be the future growth drivers. Given NFIL's dominance in the fluorination space and favourable growth outlook, we initiate coverage with a target price of ₹2,900, valuing the stock at 18x its 12M Sep'18E PE.

Exhibit 13: Business Comparison

Company	MKT CAP (₹ Cr.)	Revenue (₹ Cr.)		Rev Growth (%)			EBITDA Margin (%)		PAT Growth (%)	
		FY16	FY17E	FY18E	FY17E	FY18E	FY17E	FY18E		
SRF	8,947	4,531	10.0	12.2	21.4	21.9	18.3	18.5		
Aarti Industries	5,789	3,071	15.7	13.3	21.6	21.9	19.9	16.1		
Gujarat Fluoro. (Standalone)	5,229	1,319	36.4	16.6	28.0	30.6	176.7	29.6		
Navin Fluorine	2,479	680	12.8	16.0	20.4	21.8	37.9	24.7		
Camlin Fine Science	1,063	489	8.4	30.0	15.1	18.3	(51.3)	189.7		

Source: Bloomberg Consensus Estimates, Centrum Wealth Estimates (Navin Fluorine Intl.)

Exhibit 14: Relative Valuation


Company	MKT CAP/FY16 Sales (x)	P/E (x)		EV/EBITDA (x)		ROE (%)	
		FY17E	FY18E	FY17E	FY18E	FY17E	FY18E
SRF	1.97	17.9	15.1	10.0	8.8	17.1	17.5
Aarti Industries	1.88	15.1	12.9	9.3	8.1	25.3	24.7
Gujarat Fluoro. (Standalone)	3.96	18.2	14.0	17.2	13.4	9.5	11.4
Navin Fluorine	3.65	21.6	17.3	15.5	12.3	16.9	18.8
Camlin Fine Science	2.17	58.8	20.2	15.6	9.9	9.8	21.0

Source: Bloomberg Consensus Estimates, Centrum Wealth Estimates (Navin Fluorine Intl.) (Price data as on 3-1-2017)

Technical View on Navin Fluorine International Ltd.

- Navin Fluorine is trending strong since the past many months and has been tracing a clear higher high higher low setup in the time frame.
- The scrip is a short medium and long term buy as its structure is a well-defined bullish structure in terms of price action trend, oscillator and moving average setups.
- Buying is recommended at current juncture and on dips towards 2450-2375 range which is a trading demand range for the scrip for a six month price objective of 2950.
- Short term traders can maintain a stop loss below 2300 but overall 2190 is an ideal positional stop loss.

Exhibit 15: Technical Chart



Source: Company, Centrum Wealth Research

Financials - Consolidated

Income Statement

Y/E Mar (₹ Cr)	FY15A	FY16A	FY17E	FY18E	FY19E
Revenue	592	680	767	889	1,046
<i>Growth (%)</i>	21.7	14.9	12.8	16.0	17.6
Cost of Raw Material	289	311	333	379	446
<i>% of sales</i>	48.9	45.8	43.5	42.6	42.6
Personnel Expenses	74	81	88	100	118
<i>% of sales</i>	12.5	11.9	11.5	11.3	11.3
Other Expenses	156	171	189	217	255
<i>% of sales</i>	26.4	25.1	24.6	24.4	24.4
EBIDTA	72	117	157	194	228
EBIDTA margin %	12.2	17.3	20.4	21.8	21.8
Depreciation	20	22	26	28	30
Interest	3	4	2	2	2
Other Income	30	24	25	30	36
PBT	78	116	154	194	232
Provision for Tax	20	32	38	50	60
<i>Effective tax rate %</i>	25.6	27.7	25.0	26.0	26.0
Net Profit (Reported)	58	84	115	144	172
<i>Growth %</i>	6.5	43.4	37.9	24.7	19.6
PAT margin %	9.8	12.3	15.0	16.1	16.4

Source: Company, Centrum Wealth Research

Balance Sheet

Y/E Mar (₹ Cr)	FY15A	FY16A	FY17E	FY18E	FY19E
Share Capital	10	10	10	10	10
Reserves & Surplus	578	636	710	802	912
Shareholder's Fund	588	645	719	812	922
Total Loan Fund	61	82	82	82	82
Minority Interest	12.9	0.01	0.01	0.01	0.01
Deferred Tax Liabilities	32	37	37	37	37
Total Cap. Employed	694	764	838	930	1041
Net Fixed Assets	334	395	394	397	412
Investments	171	170	215	255	305
Cash and Bank	28	29	42	51	54
Inventories	76	76	97	102	132
Debtors	120	150	156	194	220
Loans and Advances & OCA	122	135	152	177	208
Total Current Assets	346	389	448	524	614
Current lia. and prov.	158	190	219	245	290
Net current assets	189	199	229	279	324
Total assets	694	764	838	930	1,041

Source: Company, Centrum Wealth Research, OCA: Other current asset

Cash Flow

Y/E Mar (₹ Cr)	FY15A	FY16A	FY17E	FY18E	FY19E
Cash flow from Ops					
Net Profit Before Tax	78	116	154	194	232
Depreciation and amort.	20	22	26	28	30
Others	(9)	(2)	(23)	(28)	(34)
Change in working capital	(69)	(33)	(16)	(42)	(41)
Tax expenses	(20)	(27)	(38)	(50)	(60)
Cash flow from Ops	1	76	102	101	126
Cash flow from Invest					
Capex	(62)	(18)	(25)	(30)	(45)
Other investing activities	66	(35)	(20)	(10)	(14)
Cash flow from Invest	3	(53)	(45)	(40)	(59)
Cash flow from financing					
Proceeds from eq. & warr.	0	1	-	-	-
Borrowings	(0)	7	-	-	-
Interest paid	(18)	(22)	(41)	(51)	(61)
Dividend paid	(3)	(4)	(2)	(2)	(2)
Cash flow from financing	(21)	(17)	(43)	(53)	(64)
Net Cash Flow	(17)	6	14	8	4

Source: Company, Centrum Wealth Research

Key Ratios

Y/E Mar	FY15A	FY16A	FY17E	FY18E	FY19E
Return ratios (%)					
RoE	10.2	13.5	16.9	18.8	19.8
RoCE	12.1	16.4	19.4	22.2	23.8
RoIC	14.8	18.5	22.6	27.3	30.4
Turnover Ratios (days)					
Inventory	44	41	41	41	41
Debtors	65	72	73	72	72
Creditors	46	50	50	50	50
Fixed asset turnover (x)	1.5	1.6	1.6	1.7	1.9
Solvency Ratio (x)					
Debt-equity	0.1	0.1	0.1	0.1	0.1
Interest coverage	24.5	31.6	72.1	90.9	108.5
Per share (₹)					
Adj. EPS	59.5	85.3	117.7	146.8	175.5
BVPS	600.6	659.6	735.2	829.6	942.3
CEPS	80.1	108.3	143.9	175.0	205.8
Dividend Ratios					
DPS (₹)	16.0	21.0	35.0	43.5	52.2
Dividend Yield (%)	0.6	0.8	1.4	1.7	2.1
Dividend Payout (%)	32.3	29.6	29.7	29.6	29.7
Valuation (x)					
P/E	42.7	29.8	21.6	17.3	14.5
P/BV	4.2	3.9	3.5	3.1	2.7
EV/EBIDTA	34.1	21.2	15.5	12.3	10.2
EV/Sales	4.2	3.7	3.2	2.7	2.2

Source: Company, Centrum Wealth Research

Annexure

Types of refrigerants:

- **Chlorofluorocarbons (CFCs)** – CFCs are known to contribute to the greenhouse gas effect. The production of new stocks of CFC was ceased in 1994. The most common type of CFC was R12.
- **Hydrochlorofluorocarbons (HCFCs)** – R-22, a widely used HCFC is slightly less damaging to the ozone than R12. The Montreal Protocol has set out a mandatory timetable for the phase out of all ozone-depleting substances as per which R-22 will phase out completely by 2020 from developed markets and by 2030 from developing markets.
- **Hydrofluorocarbons (HFCs)** - It includes gases like R-410A and R-134. With no chlorine in the mix, it is safer for the environment and is now being used in place of R-22. Air conditioners that run on R-410A are more efficient, offer better air quality, increase comfort and improve reliability.


Montreal Protocol

The Montreal Protocol on Substances That Deplete the Ozone Layer was a landmark international agreement designed to protect the stratospheric ozone layer. The treaty was originally signed in 1987 and substantially amended in 1990 and 1992. The Montreal Protocol stipulates that the production and consumption of compounds like chlorofluorocarbons (CFCs), halons, carbon tetrachloride, and methyl chloroform which deplete ozone in the stratosphere are to be phased out by 2000 (2005 for methyl chloroform).

Kyoto Protocol

The Kyoto Protocol is a plan created by the United Nations (UN) for the United Nations Framework Convention on Climate Change (UNFCCC) which was agreed upon in 1997. It tried to reduce the effects of climate change, such as global warming. As per the plan countries that adopt the Kyoto Protocol will have to try to reduce the amount of carbon dioxide and other greenhouse gases that are released in the air. The goals of Kyoto were to see participants collectively reducing emissions of greenhouse gases by 5.2% below the emission levels of 1990 by 2012.

Key events in the Refrigerant industry



Appendix A**Disclaimer**

Centrum Broking Limited ("CBL") is a full-service, Stock Broking Company and a member of The Stock Exchange, Mumbai (BSE), National Stock Exchange of India Ltd. (NSE) and MCX-SX Stock Exchange Limited (MCX-SX). One of our group companies, Centrum Capital Ltd is an investment banker and an underwriter of securities. As a group Centrum has Investment Banking, Advisory and other business relationships with a significant percentage of the companies covered by our Research Group. Our research professionals provide important inputs into the Group's Investment Banking and other business selection processes.

Recipients of this report should assume that our Group is seeking or may seek or will seek Investment Banking, advisory, project finance or other businesses and may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of this material/report. Our Company and Group companies and their officers, directors and employees, including the analysts and others involved in the preparation or issuance of this material and their dependants, may on the date of this report or from, time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. CBL or its affiliates do not own 1% or more in the equity of this company. Our sales people, dealers, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We may have earlier issued or may issue in future reports on the companies covered herein with recommendations/information inconsistent or different those made in this report. In reviewing this document, you should be aware that any or all of the foregoing, among other things, may give rise to or potential conflicts of interest. We and our Group may rely on information barriers, such as "Chinese Walls" to control the flow of information contained in one or more areas within us, or other areas, units, groups or affiliates of CBL. CBL and its affiliates do not make a market in the security of the company for which this report or any report was written. Further, CBL or its affiliates did not make a market in the subject company's securities at the time that the research report was published.

This report is for information purposes only and this document/material should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. It is for the general information of the clients of CBL. Though disseminated to clients simultaneously, not all clients may receive this report at the same time. Centrum will not treat recipients as clients by virtue of their receiving this report. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Similarly, this document does not have regard to the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this report may not be suitable for all investors. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. Persons who may receive this document should consider and independently evaluate whether it is suitable for his/ her/their particular circumstances and, if necessary, seek professional/financial advice. Any such person shall be responsible for conducting his/her/their own investigation and analysis of the information contained or referred to in this document and of evaluating the merits and risks involved in the securities forming the subject matter of this document.

The projections and forecasts described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. Projections and forecasts are necessarily speculative in nature, and it can be expected that one or more of the estimates on which the projections and forecasts were based will not materialize or will vary significantly from actual results, and such variances will likely increase over time. All projections and forecasts described in this report have been prepared solely by the authors of this report independently of the Company. These projections and forecasts were not prepared with a view toward compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these projections or forecasts. You should not regard the inclusion of the projections and forecasts described herein as a representation or warranty by or on behalf of the Company, CBL, Centrum group, the authors of this report or any other person that these projections or forecasts or their underlying assumptions will be achieved. For these reasons, you should only consider the projections and forecasts described in this report after carefully evaluating all of the information in this report, including the assumptions underlying such projections and forecasts.

The price and value of the investments referred to in this document/material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. Future returns are not guaranteed and a loss of original capital may occur. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. We do not provide tax advice to our clients, and all investors are strongly advised to consult regarding any potential investment. CBL and its affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk. Certain transactions including those involving futures, options, and other derivatives as well as non-investment-grade securities give rise to substantial risk and are not suitable for all investors. Please ensure that you have read and understood the current risk disclosure documents before entering into any derivative transactions.

This report/document has been prepared by CBL, based upon information available to the public and sources, believed to be reliable. No representation or warranty, express or implied is made that it is accurate or complete. CBL has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The opinions expressed in this document/material are subject to change without notice and have no obligation to tell you when opinions or information in this report change.

This report or recommendations or information contained herein do/does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced, transmitted or published by the recipient. The report is for the use and consumption of the recipient only. This publication may not be distributed to the public used by the public media without the express written consent of CBL. This report or any portion hereof may not be printed, sold or distributed without the written consent of CBL.

The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Neither CBL nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

This document does not constitute an offer or invitation to subscribe for or purchase or deal in any securities and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. This document is strictly confidential and is being furnished to you solely for your information, may not be distributed to the press or other media and may not be reproduced or redistributed to any other person. The distribution of this report in other jurisdictions may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. By accepting this report, you agree to be bound by the foregoing limitations. No representation is made that this report is accurate or complete.

The opinions and projections expressed herein are entirely those of the author and are given as part of the normal research activity of CBL and are given as of this date and are subject to change without notice. Any opinion estimate or projection herein constitutes a view as of the date of this report and there can be no assurance that future results or events will be consistent with any such opinions, estimate or projection.

This document has not been prepared by or in conjunction with or on behalf of or at the instigation of, or by arrangement with the company or any of its directors or any other person. Information in this document must not be relied upon as having been authorized or approved by the company or its directors or any other person. Any opinions and projections contained herein are entirely those of the authors. None of the company or its directors or any other person accepts any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

CBL and its affiliates have not managed or co-managed a public offering for the subject company in the preceding twelve months. CBL and affiliates have not received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for service in respect of public offerings, corporate finance, debt restructuring, investment banking or other advisory services in a merger/acquisition or some other sort of specific transaction.

As per the declarations given by his/her, research analyst and the author of this report and/or any of his/her family members do not serve as an officer, director or any way connected to the company/companies mentioned in this report. Further, as declared by his/her, he/she has not received any compensation from the above companies in the preceding twelve months. Our entire research professionals are our employees and are paid a salary. They do not have any other material conflict of interest of the research analyst or member of which the research analyst knows of has reason to know at the time of publication of the research report or at the time of the public appearance.

While we would endeavour to update the information herein on a reasonable basis, CBL, its associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Centrum from doing so.

Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Centrum policies, in circumstances where CBL is acting in an advisory capacity to this company, or any certain other circumstances.

This report is not directed to or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Centrum Broking Limited or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market.

Disclosures under the SEBI (Research Analysts) Regulations 2014

Disclosure of Interest Statement		
1	Business activities of Centrum Broking Limited (CBL)	Centrum Broking Limited (hereinafter referred to as "CBL") is a registered member of NSE (Cash, F&O and Currency Derivatives Segments), MCX-SX (Currency Derivatives Segment) and BSE (Cash segment), Depository Participant of CDSL and a SEBI registered Portfolio Manager.
2	Details of Disciplinary History of CBL	CBL has not been debarred/ suspended by SEBI or any other regulatory authority from accessing /dealing in securities market.
3	Registration status of CBL	CBL is registered with SEBI as a Research Analyst (SEBI Registration No. INH000001469)

4	Whether Research analysts or relatives' have any financial interest in the subject company and nature of such financial interest	No
5	Whether Research analysts or relatives have actual / beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the document.	No
6	Whether the research analysts or his relatives has any other material conflict of interest	No
7	Whether research analysts have received any compensation from the subject company in the past 12 months and nature of products / services for which such compensation is received	No
8	Whether the Research Analysts have received any compensation or any other benefits from the subject company or third party in connection with the research report	No
9	Whether Research Analysts has served as an officer, director or employee of the subject company	No
10	Whether the Research Analysts has been engaged in market making activity of the subject company.	No

Member (and BSE)**Regn No.:**

CAPITAL MARKET SEBI REGN. NO.: BSE: INB011454239
 CAPITAL MARKET SEBI REGN. NO.: NSE: INB231454233
 DERIVATIVES SEBI REGN. NO.: NSE: INF231454233
 (TRADING & CLEARING MEMBER)
 CURRENCY DERIVATIVES: MCX-SX INE261454230
 CURRENCY DERIVATIVES:NSE (TM & SCM) – NSE 231454233

Depository Participant (DP)

CDSL DP ID: 120 – 12200
 SEBI REGD NO. : CDSL : IN-DP-CDSL-661-2012

PORTFOLIO MANAGER

SEBI REGN NO.: INP000004383

Website: www.centrum.co.in

Investor Grievance Email ID: investor.grievances@centrum.co.in

Compliance Officer Details:

Kavita Ravichandran
 (022) 4215 9842; Email ID: compliance@centrum.co.in

Centrum Broking Ltd. (CIN: U67120MH1994PLC078125)

REGD. OFFICE Address Bombay Mutual Bldg., 2nd Floor, Dr. D.N. Road, Fort, Mumbai - 400 001	Corporate Office & Correspondence Address Centrum House 6th Floor, CST Road, Near Vidya Nagari Marg, Kalina, Santacruz (E) Mumbai 400 098. Tel: (022) 4215 9000 Fax: +91 22 4215 9344
---	--